m6A-modified circQSOX1 promotes glycolysis and immune escape in CRC by regulating the miR-326/miR-330-5p/PGAM1 axis and inhibits the response to CTLA-4 antibody immunotherapy in CRC patients, leading to immunotherapy resistance (Liu et al., 2022d). Here, PGAM1 is linked to colorectal carcinoma.